Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen-Reference-Cited by-同舟云学术

Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen

Published:2015-08 Issue:8 Volume:21 Page:1460-1470
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Marsh Rebecca A.,Rao Marepalli B.,Gefen Aharon,Bellman Denise,Mehta Parinda A.,Khandelwal Pooja,Chandra Sharat,Jodele Sonata,Myers Kasiani C.,Grimley Michael,Dandoy Christopher,El-Bietar Javier,Kumar Ashish R.,Leemhuis Tom,Zhang Kejian,Bleesing Jack J.,Jordan Michael B.,Filipovich Alexandra H.,Davies Stella M.

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference26 articles.

1. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome–single center experience;Rzepecki;Jpn J Clin Oncol,2006

2. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation;Marsh;Blood,2010

3. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis;Marsh;Biol Blood Marrow Transplant,2013

4. Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen;Hansen;Bone Marrow Transplant,2008

5. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders;Shenoy;Bone Marrow Transplant,2005

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention;Blood Advances;2024-08-15

2. Treatment of relapsed/refractory severe aplastic anemia in children: Evidence‐based recommendations;Pediatric Blood & Cancer;2024-05-19

3. Effect of allogeneic hematopoietic stem cell transplantation for chronic granulomatous disease in children: A multicentre, retrospective cohort study in China;Clinical Immunology;2024-03

4. The role of graft T-cell size in patients receiving alemtuzumab serotherapy for non-malignant disorders: results of an institutional protocol;Scientific Reports;2024-01-10

5. Age Impacts Risk of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Non-Severe Combined Immune Deficiency Inborn Errors of Immunity;Transplantation and Cellular Therapy;2024-01